How many investments has XGEN Venture made?

XGEN Venture has 11 tracked investments.

What stage does XGEN Venture invest at?

XGEN Venture invests at the Pre-Seed, Seed, Series A stages.

What sectors does XGEN Venture focus on?

XGEN Venture focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is XGEN Venture located?

XGEN Venture is headquartered in Milan, IT.

Who does XGEN Venture co-invest with?

XGEN Venture most often shares deals with Indaco Venture Partners, Sofinnova Partners, CDP Venture Capital, among 24 tracked co-investors.

XGEN Venture

Venture capitaloperating company · company profile

Milan · Pre-Seed–Series A · 21 people tracked

Also known as XGen Venture SGR

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into XGEN Venture

2,583 people in our graph share verified history with the XGEN Venture team — schools, employers, funds. One of them is your warm intro.

Chris Bischoffunlockedknows Michele Manto · together at INSEAD (overlapped)

knows the team · via INSEAD

×2knows the team · via McKinsey & Company

knows the team · via Smith+Nephew

knows the team · via APIM Therapeutics

knows the team · via Boston Scientific

✨ Fox Verdict

Investment thesis

XGEN Venture specializes in early-stage investments in private research and development companies within the life sciences sector, aiming to build next-generation life science ventures. Established by the former Genextra team, the firm draws on over 15 years of experience in the startup process and in the discovery and development of novel solutions for high unmet medical needs. It is currently deploying capital from its first fund, XGEN Venture Life Science Fund, launched at the end of 2022, while continuing to advise Genextra's board of directors on managing its existing portfolio.

Invests inBiotech Digital Health Healthtech Medical Devices Europe Germany Italy Milan North America Switzerland

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Series A

Milan, IT

Instruments

Equity

Founded

2021

AUM

$194.4M

Tracked investments

Team · 21 people

from the firm's website & public directories

Daniele Scarinci· Founder & Managing Partner· Milan, ITin

Co-founder and Managing Partner of XGEN (2021), previously Investment Director at Genextra since 2006. Chairman of Tethis and board member of Kuste Biopharma and Page Therapeutics. Holds a degree in Economics of Financial Markets from Tor Vergata University.

d•••@xgenventure.comreveal

Federica Draghi· Founder & Managing Partner· Milan, ITin

Co-founder and Managing Partner of XGEN (2021) with extensive life sciences and venture capital experience. Former Investment Director at Genextra and co-founder of Italian Angels for Biotech. Holds an MBA from Columbia and a PhD in protein crystallography.

f•••@xgenventure.comreveal

Paolo Fundarò· Founder & Managing Partner· Milan, ITin

Co-founder and Managing Partner of XGEN (2021) and CEO of XGEN Venture SGR. Was at Genextra from 2004, serving as CEO until 2022. Board member for several biotechs and co-founder of Italian Angels for Biotech. Holds a degree from Bocconi University.

p•••@xgenventure.comreveal

Bastiaan van der Baan· Venture Partner· Amsterdam, NLin

Biotech executive with 20+ years focused on oncology and diagnostics, most recently Chief Clinical Officer of Agendia. Co-founder of ThromboDx, Qameleon Therapeutics and Oncosence. Joined XGEN in 2023.

Bertil Lindmark· Venture Partner· Copenhagen, DKin

Biopharma professor with senior global roles at AstraZeneca and Almirall and various biotech companies, focused on respiratory, immunology and cancer. Currently Chairman of Aqilion AB and CMO at Galecto Inc. Joined XGEN in 2023.

Gokhan Batur· Venture Partner· Zurich, CHin

Healthcare executive with 19 years of experience, formerly CEO of Swiss biotech Polyphor and a global brand leader at MSD/Merck. Board member at APIM Therapeutics and advisor to biotechs in Europe and the US. Joined XGEN in 2023.

Keith Dawkins· Venture Partner· London, UKin

Cardiologist and medtech executive, board member of Ventric Health, JenaValve, Protembis and chairman of InnovHeart. Previously Global Chief Medical Officer at Shockwave Medical and Boston Scientific. Joined XGEN in 2023.

Khatereh Ahmadi· Venture Partner· London, England, United Kingdomin

Pharmaceutical industry executive with 20+ years of experience across large pharma and biotech startups. Former Head of Search and Evaluation at MSD, co-founder and CEO of reViral (acquired by Pfizer), and NED on the board of Guard Therapeutics. Holds a PhD in Biochemistry from King's College London and an MBA.

Luca Quagliata· Venture Partner· Napoli, ITin

VP and Global Head of Medical Affairs for the Genetic Science Group at Thermo Fisher Scientific, previously at the Institute of Pathology, University Hospital Basel. Holds a PhD in Vascular Medicine and is a Board-Certified Specialist in Medical Affairs. Joined XGEN in 2023.

Marija Zecevic· Venture Partner· Boston, USAin

Biotech executive with 20+ years across public and private companies in the US and Europe, currently Chief Business Officer at a Boston neuroscience drug development company. Holds a PhD in Biochemistry from the University of Zurich. Joined XGEN in 2023.

Michele Manto· Venture Partner· Milan, ITin

Commercial pharma executive, currently Chief Commercial Officer, Western Europe at Alfasigma, and formerly CCO at Galapagos and a leader at AbbVie. Started at McKinsey. Holds an MBA from INSEAD. Joined XGEN in 2023.

Victor Savevski· Venture Partner· Milan, ITin

Chief Innovation Officer and AI Center Director at Humanitas and adjunct professor in AI and digital health at Humanitas University. Has launched over 50 digital health products used by 90+ million users. Joined XGEN in 2023.

Bianca Benatti· Jr. Analyst· Monza, Lombardy, Italyin

Junior analyst who joined XGEN in June 2025, supporting due diligence and scouting. Previously conducted machine learning research on neuro-biological data at San Raffaele Hospital. Graduated in Psychology and Neurosciences from Vita-Salute San Raffaele University.

Carlotta Marchese· Regulatory and Corporate Affairs Specialist· Milan, ITin

Joined XGEN in October 2024 focusing on regulatory and corporate affairs. Previously a consultant supporting internal audit, compliance and AML functions for financial intermediaries. Holds a degree in International Law from Bocconi University.

Graziano Piredda· Sr. Analyst· Milan, Lombardy, Italyin

Senior Analyst who joined XGEN in June 2025, contributing to deal analysis, financial modeling and portfolio monitoring. Previously worked in the financial markets divisions of Enel and Banca Sella. Holds an MBA from SDA Bocconi.

Laura Pizzi· Office Manager· Milan, ITin

Office Manager and Executive Assistant at XGEN since 2022. Previously worked at investment firms including Genextra, Indaco Venture Partners and Europa Investimenti. Holds a degree in Public Relations from IULM University.

Luca Porro· MedTech Specialist· Milan, ITin

Joined XGEN in 2024 as a MedTech advisor with 18 years in medical technology. Founder of consulting firm AlpiMedical and a business angel with Club degli Investitori. Spent 15 years at Sorin and LivaNova. Holds an MBA from ESCP.

Mariagiulia Davide· Analyst· Milan, ITin

Analyst at XGEN since October 2022 supporting investment activities, operations and ESG functions. Formerly a business analyst at Tethis and a public sector consultant at EY. Graduated in Economics and Management from Bocconi University.

Monica Pala· Administrative Manager· Milan, IT

Administrative Manager at XGEN since 2022 responsible for bookkeeping, tax, reporting and compliance. Previously Administration Manager at Genextra since 2007. Holds a degree in Economics from Università Cattolica, Milan.

Roberto Molinaro· Associate· Milan, ITin

Associate at XGEN since 2022 supporting deal scouting and due diligence. Brings 10+ years in nanotechnology and personalized nanomedicine research at Houston Methodist, Harvard Medical School and University of Urbino.

r•••@xgenventure.comreveal

Simona Varani· Investment Manager· Milan, ITin

With XGEN as Associate since October 2022. Previously IP manager at Fondazione Telethon, partner at Zebra Ventures, and IP manager at Bioxell. Holds a master in Intellectual Property Law from the University of Strasbourg.

s•••@xgenventure.comreveal

Founder mafia

3 people who came through XGEN Venture went on to found or lead other companies.

Daniele ScarinciFounder & Managing PartnerFounded Page Therapeutics Khatereh AhmadiVenture PartnerFounded ReViral Bastiaan van der BaanVenture PartnerFounded Lixte Biotechnology Holdings

What they invest in

from 7 of 11 portfolio companies

Biotech ×6Healthtech ×4Medical Devices ×4Deep Tech ×3Digital Health ×3FemTech ×1

HQs:Italy×2Germany×1Sweden×1

Investments · 11 tracked

founders shown can be your intro path

Genespiregenespire.com✓ verified

Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners.

BiotechDeep TechDigital HealthHealthtech

Dr. Lucia Faccio(Chief Executive Officer)inDr. Julianne Smith(Chief Development Officer)Dr. Simon Hawkins(VP Clinical Development)Dr. Smaragda Angelidou(Responsabile CMC)Dr. Mary Wang(Patient Engagement Director)Emanuela Balzo(VP of Finance)in

Co-investorsCDP Venture Capital Indaco Venture Partners Sofinnova Partners

Gesynta Pharmagesynta.se in✓ verified

Gesynta Pharma is a pharmaceutical company developing non-hormonal, anti-inflammatory drug candidates that inhibit the mPGES-1 enzyme, with a lead program in endometriosis.

BiotechDigital HealthFemTechMedical DevicesStockholm, SE

Patric Stenberg(Founder)Gunilla Ekström(Founder)in

Co-investorsAmboy Street Ventures Foreground Capital Hadean Ventures HealthCap Industrifonden Catalyze Capital

Nanophoriananophoria.com in✓ verified

NanoPhoria is a life sciences company that raised an €83.5 million Series A round.

BiotechDeep TechMedical Devices

Daniele Catalucci inMichele IafiscoAlessio AlognaClaudio De Lucain

Co-investorsSofinnova Partners CDP Venture Capital European Innovation Council Fund

Epilepsy GTxepilepsygtx.com in

EpilepsyGTx is a preclinical-stage biotech developing gene therapies for focal refractory epilepsy (FRE), with the aim of making patients seizure free.

BiotechDigital Health

Co-investorsAlbionVC Moonstone Venture Capital UCL Technology Fund British Business Bank

iOncturaionctura.com in 𝕏

iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.

BiotechDeep TechHealthtechMedical Devices

Catherine Pickering(Co-Founder & CEO)in Lars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in

Co-investorsInkef 3B Future Health Fund M Ventures VI Partners

Page Therapeuticspagetherapeutics.com in

PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis.

BiotechHealthtech

Nicola Aceto(Co-founder & Chief Science Officer)in Christoph Rochlitz(Co-founder & Chief Medical Officer)in Daniele Scarinci(CEO & Executive Director)inKatharina Venturi(Chief Operating Officer)in

Co-investorsClaris Ventures

Protembisprotembis.com inMar 2024

Protembis is a German medical device company developing the ProtEmbo Cerebral Protection System, an intra-aortic filter device inserted via the left radial artery that shields the brain from embolic debris during transcatheter aortic valve replacement (TAVR) and other left-sided heart procedures.

HealthtechMedical DevicesAachen, DE

Karl von Mangoldt(Co-Chief Executive Officer)inConrad Rasmus(Co-Chief Executive Officer)inOliver Marseille(CTO)

Co-investorsEuropean Investment Bank TechVision Fonds coparion TechVision Fund

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AavantgardeAAVantgarde BioNouscomTes Pharma

Portfolio news

latest coverage across their companies

EpilepsyGTx secures $33m to progress FRE therapy through Phase I/IIa trials

Epilepsy GTx · clinicaltrialsarena.com · Dec 11, 2025

Nanophoria, record funding of 83 million to revolutionize cardiovascular therapies - INT News Nanophoria record financing of 83 million

Nanophoria · intnews.it · Oct 8, 2025

Gesynta Pharma Adds $3.9M in Series B Funding for Endometriosis Drug, Total Round Reaches $31.5M | Femtech Insider

Gesynta Pharma · femtechinsider.com · Jul 23, 2025

iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair

iOnctura · prnewswire.com · Mar 17, 2025

Frequently asked questions

How many investments has XGEN Venture made?: XGEN Venture has 11 tracked investments.
What stage does XGEN Venture invest at?: XGEN Venture invests at the Pre-Seed, Seed, Series A stages.
What sectors does XGEN Venture focus on?: XGEN Venture focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is XGEN Venture located?: XGEN Venture is headquartered in Milan, IT.
Who does XGEN Venture co-invest with?: XGEN Venture most often shares deals with Indaco Venture Partners, Sofinnova Partners, CDP Venture Capital, among 24 tracked co-investors.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

CABHI Ventures

CABHI (Centre for Aging + Brain Health Innovation) is a pan-Canadian organization that funds and supports researchers, innovators, and startups working on brain health and aging solutions, and helps healthcare and community organizations adopt them.